Aeon Biopharma, Inc. · AMEX:AEON
Aeon Biopharma — Aegis Capital Healthcare Conference May 2025
14 slides from Aeon Biopharma's conference presentation, May 20, 2025
Slide 1: Corporate Presentation - Aegis Capital Healthcare Conference May 2025
Corporate Presentation - Aegis Capital Healthcare Conference May 2025 PrabotulinumtoxinA Redefining access to therapeutic botulinum toxins
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation includes forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements concerning possible or assumed future actions, business strategies, events or results of operations, and a
Slide 3: Redefining Access to Therapeutic Neurotoxins Through Biosimilarity
3 Redefining Access to Therapeutic Neurotoxins Through Biosimilarity • Developing ABP-450, a 900kD botulinum toxin, as a biosimilar to Botox® • Goal: match full range of Botox® approved therapeutic indications • Building on global biosimilar approvals and FDA-approved manufacturing* BPD: Biosimilar
Slide 4: A Rare Biosimilar Opportunity – with a Running Start
4 A Rare Biosimilar Opportunity – with a Running Start 1. Structural similarity based on comparison of ABP-450 to Botox® published literature, not a head-to-head study. Comparative analytical testing of primary structure is expected to be completed in the second half of 2025. 2. Developed and commer
Slide 5: Built for Biosimilarity: A Team with Deep Toxin Experience
5 Backed by strong capital and financial leadership Built for Biosimilarity: A Team with Deep Toxin Experience Rob Bancroft Chad Oh, MD Chief Executive Officer Chief Medical Officer • 25+ years life sciences leadership • Led Daxxify® therapeutic launch at Revance; was engaged in biosimilar partnersh
Slide 6: Botox Commands 95% of >$2.8B U.S. Market – But Cost Limits Access
6 Consistent category growth despite concentrated brand share and payer cost fatigue Botox® Commands 95% of >$2.8B U.S. Market – But Cost Limits Access Source: AbbVie, Inc. quarterly earnings reports • Organic growth: Continued penetration of existing indications driven by high clinical utility and
Slide 7: ABP-450 Matches Botox in Molecular Size – and Can Match Its Label
7 ABP-450 Matches Botox® in Molecular Size – and Can Match Its Label AbbVie Inc. Merz Pharma Ipsen Group Crown Laboratories Molecular Size 900 kDa 900 kDa 150 kDa ~400 kDa 150 kDa FDA Approved Therapeutic Indications 1. Chronic migraine 2. Overactive bladder 3. Detrusor overactivity 4. Pediatric det
Slide 8: ABP-450 is Advancing Through the FDA Biosimilar Pathway
8 FDA uses a stepwise, totality-of-evidence approach – basing additional requirements on the level of residual uncertainty ABP-450 is Advancing Through the FDA Biosimilar Pathway 1. Manufacturing facilities for therapeutics use would require separate regulatory inspection https://www.fda.gov/drugs/b
Slide 9: FDA precedent supports broad label access – Extrapolation: Potential Full Indication Capture
9 FDA precedent supports broad label access – unlocking full Botox® market potential for ABP-450 Extrapolation: Potential Full Indication Capture Without Redundant Trials 1. https://www.fda.gov/drugs/biosimilars/review-and-approval Chronic migraine Cervical dystonia Adult upper limb spasticity Adult
Slide 10: AEON's Therapeutics-Only BLA Avoids ASP Compression from Aesthetics
10 Decoupled ASP → attractive & stable provider cost recovery → amplifies impact of payer contracting levers AEON’s Therapeutics-Only BLA Avoids ASP* Compression from Aesthetics *Average selling price Value to Payer Ability to implement utilization controls and drive preferred product adoption Value
Slide 11: Modern Biosimilars Are Achieving Rapid Market Penetration
11 Recent biosimilars hit 70% share within 3 years of launch Modern Biosimilars Are Achieving Rapid Market Penetration Reproduced with permission; IQVIA “Biosimilars in the United States 2023-2027” IQVIA MIDAS, IQVIA DDD, Oct 2022; IQVIA Institute, Dec 2022
Slide 12: Buy-and-Bill Dynamics Accelerate Physician-Driven Biosimilar Adoption
12 Physician-administered settings have reached nearly 60% biosimilar share in 2 years Buy-and-Bill Dynamics Accelerate Physician-Driven Biosimilar Adoption Reproduced with permission; IQVIA “Biosimilars in the United States 2023-2027” IQVIA LAAD Medical Procedures Claims, Sep 2022; US Market Access
Slide 13: Significant Share Gains Have Not Required Deep Price Cuts
13 Top-performing biosimilars gained share at 18–50% discounts — not a race to the bottom Significant Share Gains Have Not Required Deep Price Cuts Reproduced with permission; IQVIA “Biosimilars in the United States 2023-2027” IQVIA National Sales Perspective, US Market Access Strategy Consulting, D
Slide 14: AEON Biopharma: A High-Conviction Play in Biosimilar Innovation
14 14 AEON Biopharma: A High-Conviction Play in Biosimilar Innovation Accelerated Biosimilar Pathway Only Toxin Positioned to Match Botox® Label Untethered ASP Advantage Catalysts Ahead 900kD structure + completed assays, FDA-approved manufacturing*, and positive Phase 2 cervical dystonia data suppo
AEON Biopharma — Aegis Capital Healthcare Conference May 2025 on 6ix